


**SYSTEM FOR TARGETED DELIVERY AND CONTROLLED DRUG RELEASE**

A novel targeted drug delivery and release system has been developed and successfully tested in a xenograft tumor model. The system consists of nanoparticles equipped with tumor targeting peptides. These particles are designed to carry drugs that can be released by locally applying a magnetic field. First proof-of-concept *in vivo* studies for a tumor targeting nanosystem have been successful.

A patient derived xenograft tumor model in the mouse was used. Initial results show no side effects (figure 2, 3) but a significant inhibition of tumor growth (figure 1). Furthermore the delivery and release system is more efficient than the standard therapy with the non-encapsulated drug.

This system was developed by a multidisciplinary group of partners including **AIN** (Spain), **EPO Berlin** (Germany), **Idifarma** (Spain), and **IZI** (Germany). This consortium comprises of partners with expertise in the pharmaceutical and biotechnological field and capacities to develop drug formulations, pilot-scale GMP manufacturing, DMPK and preclinical studies.

We are presently looking for industrial collaborators to further develop the system and as future licensing partners.



**PROOF OF CONCEPT: INHIBITION OF TUMOR GROWTH**


**Figure 1: Xenograft tumor model treated with nanocarrier for targeted drug delivery and triggered drug release.**

Renal PDX REN11619 bearing mice were treated at day 0, 2 and 4 after stratification with the nanocarrier, followed by magnet field exposure 2 h post treatment.

#: significantly different to control;  
\*: significantly different to SOC,  
+: significantly different to Exposure.  
Mann-Whitney nonparametric U-test, p<0.05.

SOC = Standard operation protocol  
NC = Nanocarrier

**NO SIDE EFFECTS DUE TO TARGETED DRUG DELIVERY AND RELEASE**



**Figure 2: Impact of treatment on body weight and blood composition**

(A) REN11619 bearing mice were treated at day 0, 2 and 4 after stratification and body weight was measured at indicated days. (B) Blood samples were taken at day 36 and analyzed for composition. Treatments: (A) Saline, (B) SOC, (C) Exposure, (D) NC+Exposure, (E) SOC + Exposure

SPONSORED BY THE

